群英荟萃，智慧闪耀。肿瘤领域年度盛会2024美国临床肿瘤学会（ASCO 2024）年会即将于2024年5月31日~6月4日在美国芝加哥举行。
近日，ASCO官网公布了摘要题目及讲者信息。【肿瘤资讯】特别整理
全体大会（Plenary Session）、口头摘要专场（Oral Abstract Session）、临床科学研讨会（Clinical Science Symposium）、口头摘要速递专场（Rapid Oral Abstract Session）的肺癌领域研究，与读者分享。
全体大会（Plenary Session）
摘要号：LBA3
Comparative effectiveness trial of early palliative care delivered via telehealth versus in person among patients with advanced lung cancer.
晚期肺癌患者通过远程医疗与面对面就医进行早期姑息治疗的比较有效性试验
讲者：Joseph A. Greer, PhD | Massachusetts General Hospital, Harvard Medical School
摘要号：LBA4
Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study.
不可切除的III期EGFR突变NSCLC患者在确定性放化疗（CRT）后接受奥希替尼治疗：3期LAURA研究的主要结果
讲者：Suresh S. Ramalingam, MD, FASCO, FACP | Emory University School of Medicine, Winship Cancer Institute
摘要号：LBA5
ADRIATIC: durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC).
ADRIATIC：度伐利尤单抗作为局限期小细胞肺癌（LS-SCLC）患者的巩固治疗
讲者：David R. Spigel, MD, FASCO | Sarah Cannon Research Institute
口头摘要专场（Oral Abstract Session）
转移性非小细胞肺癌
摘要号：LBA8500
Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1inhibitors (IO): Primary results from the phase 3 EVOKE-01 study.
戈沙妥珠单抗（SG）对比多西他赛（doc）治疗既往接受过铂类化疗（PT）和PD(L)-1抑制剂（IO）治疗的转移性非小细胞肺癌（mNSCLC）患者：3期EVOKE-01研究的初步结果
讲者：Luis G. Paz-Ares, PhD | Hospital Universitario 12 De Octubre
摘要号：8501
ICARUS-LUNG01: A phase 2 study of datopotomab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC), with sequential tissue biopsies and biomarkers analysis to predict treatment outcome.
ICARUS-LUNG01：一项针对既往接受过治疗的晚期NSCLC患者的datopotomab deruxtecan (Dato-DXd)2期研究，通过连续组织活检和生物标记物分析来预测治疗效果。
讲者：David Planchard, MD, PhD | Department of Medical Oncology, Thoracic Group, Gustave Roussy
摘要号：8502
Sacituzumab tirumotecan (SKB264/MK-2870) in combination with KL-A167 (anti-PD-L1) as first-line treatment for patients with advanced NSCLC from the phase II OptiTROP-Lung01 study.
Sacituzumab tirumotecan (SKB264/MK-2870)联合KL-A167(PD-L1单抗)一线治疗晚期NSCLC II期OptiTROP-Lung01研究
讲者：方文峰 中山大学肿瘤防治中心
摘要号：LBA8503
Lorlatinib vs crizotinib in treatment-naïve patients with advanced ALK+ non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study.
洛拉替尼 vs 克唑替尼治疗初治晚期ALK+非小细胞肺癌患者：CROWN研究的5年PFS和安全性。
讲者：Benjamin J. Solomon, PhD, MBBS | Department of Medical Oncology, Peter MacCallum Cancer Centre
摘要号：8504
Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer (NSCLC) with biomarkers of high-risk disease: A secondary analysis from the phase 3 MARIPOSA study.
Amivantamab+lazertinib vs 奥希替尼一线治疗具有高风险疾病生物标志物的EGFR突变晚期NSCLC：MARIPOSA 3期研究的二次分析
讲者：Enriqueta Felip, MD, PhD | Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology
摘要号：LBA8505
Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial.
皮下注射amivantamab vs 静脉注射amivantamab，均联合lazertinib，治疗难治性EGFR突变的晚期NSCLC：来自全球3期随机对照PALOMA-3试验的主要结果，包括总生存期（OS）
讲者：Natasha B. Leighl, MD, FASCO | Princess Margaret Cancer Centre
摘要号：8506
NRG-LU002: Randomized phase II/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC).
NRG-LU002：维持系统治疗 vs 局部巩固治疗（LCT）+维持系统治疗局限性转移性NSCLC的随机II/III期试验
讲者：Puneeth Iyengar, MD, PhD | Memorial Sloan Kettering Cancer Center
摘要号：8508
Ivonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment (HARMONi-A): A randomized, double-blind, multi-center, phase 3 trial.
Ivonescimab联合化疗用于EGFR-TKI治疗进展的EGFR突变非鳞状NSCLC(HARMONi-A)：一项随机、双盲、多中心、3期试验
讲者：张力 中山大学肿瘤防治中心
局晚期非小细胞肺癌/小细胞肺癌/其他胸部肿瘤
摘要号：8001
BEAT-SC: A randomized phase III study of bevacizumab or placebo in combination with atezolizumab and platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC).
BEAT-SC：贝伐珠单抗或安慰剂联合阿替利珠单抗和含铂化疗治疗广泛期小细胞肺癌（ES-SCLC）患者的随机III期研究
讲者：Yuichiro Ohe, MD, PhD | National Cancer Center Hospital
摘要号：LBA8002
BEAT-meso: A randomized phase III study of bevacizumab (B) and standard chemotherapy (C) with or without atezolizumab (A), as first-line treatment (TX) for advanced pleural mesothelioma (PM)—Results from the ETOP 13-18 trial.
BEAT—meso：贝伐珠单抗和标准化疗联合或不联合阿替利珠单抗作为晚期胸膜间皮瘤（PM）一线治疗的随机III期研究—ETOP 13—18试验结果
讲者：Sanjay Popat, PhD, FRCP | Royal Marsden Hospital NHS Foundation Trust
摘要号：8003
Feasibility and safety of neoadjuvant nivolumab and chemotherapy for resectable diffuse pleural mesotheliomas: Results of a prospective pilot study.
新辅助纳武利尤单抗和化疗治疗可切除弥漫性胸膜间皮瘤的可行性和安全性：一项前瞻性初步研究的结果
讲者：Michael Offin, MD | Memorial Sloan Kettering Cancer Center
摘要号：8004
Adjuvant icotinib of 12 months or 6 months versus observation following adjuvant chemotherapy for resected EGFR-mutated stage II–IIIA non-small-cell lung cancer (ICTAN, GASTO1002): A randomized phase 3 trial.
辅助埃克替尼治疗12个月或6个月与观察对照，作为可切除EGFR突变II-IIIA期非小细胞肺癌辅助化疗后的治疗方案（ICTAN，GASTO1002）：一项随机3期试验
讲者：王思愚 中山大学肿瘤防治中心
摘要号：8005
Molecular residual disease (MRD) analysis from the ADAURA trial of adjuvant (adj) osimertinib in patients (pts) with resected EGFR‑mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC).
ADAURA试验中奥希替尼辅助治疗（adj）可切除EGFR突变（EGFRm）IB-IIIA期NSCLC患者的分子残留病灶（MRD）分析
讲者：Tom John, PhD, FRACP, MBBS | Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne
摘要号：8006
Health-related quality of life (HRQoL) results for adjuvant alectinib vs chemotherapy in patients with resected ALK+ non-small cell lung cancer (NSCLC): Data from ALINA.
可切除ALK+NSCLC患者中辅助阿来替尼 vs 化疗的健康相关生活质量（HRQoL）结果：数据来自ALINA
讲者：Makoto Nishio, MD, PhD | Cancer Institute Hospital of Japanese Foundation for Cancer Research
摘要号：LBA8007
Clinical outcomes with perioperative nivolumab (NIVO) by nodal status among patients (pts) with stage III resectable NSCLC: Results from the phase 3 CheckMate 77T study.
III期可切除NSCLC患者中按淋巴结状态划分的围手术期使用纳武利尤单抗（NIVO）的临床结局：3期CheckMate 77T研究的结果
讲者：Tina Cascone, MD, PhD | The University of Texas MD Anderson Cancer Center
摘要号：8008
A phase II randomized trial evaluating consolidative nivolumab in locally advanced non-small cell lung cancer post neoadjuvant chemotherapy plus nivolumab and concurrent chemoradiotherapy (GASTO-1091).
一项评估局部晚期非小细胞肺癌新辅助化疗+纳武利尤单抗和同步放化疗后纳武利尤单抗巩固治疗的II期随机试验(GASTO-1091)
讲者：刘慧 中山大学肿瘤防治中心
摘要号：8009
Taiwan national lung cancer early detection program for heavy smokers and non-smokers with family history of lung cancer.
台湾（中国）地区对于重度吸烟以及有肺癌家族史的非吸烟人群肺癌早期筛查计划
讲者：Pan-Chyr Yang （中国）台湾大学医学院
临床科学研讨会（Clinical Science Symposium）
靶向KRAS治疗非小细胞肺癌
摘要号：LBA8509
KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation
在既往接受过治疗的携带KRASG12C突变的晚期/转移性NSCLC患者中比较adagrasib与多西他赛的III期研究
讲者：莫树锦 （中国）香港中文大学
摘要号：8510
Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC.
第二代KRAS G12C抑制剂（G12Ci）olomorasib（LY3537982）与帕博利珠单抗联合治疗KRAS G12C突变晚期NSCLC患者的疗效和安全性。
讲者：Timothy F. Burns, MD, PhD | Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Medical Center Hillman Cancer Center
摘要号：LBA8511
KROCUS: A phase II study investigating the efficacy and safety of fulzerasib (GFH925) in combination with cetuximab in patients with previously untreated advanced KRAS G12C mutated NSCLC.
KROCUS：一项II期研究，旨在研究fulzerasib（GFH 925）联合西妥昔单抗治疗既往未经治疗的晚期KRAS G12C突变NSCLC患者的疗效和安全性
讲者：Vanesa Gregorc, MD | Candiolo Cancer Institute, FPO-IRCCS
摘要号：8512
Sotorasib plus carboplatin and pemetrexed in KRAS G12C advanced NSCLC: Updated analysis from the international CodeBreaK 101 trial.
Sotorasib联合卡铂和培美曲塞治疗KRAS G12C晚期NSCLC：来自国际CodeBreak 101试验的更新分
讲者：Bob T. Li, MD, PhD, MPH, FRACP | Memorial Sloan Kettering Cancer Center
下一代ADC
摘要号：103
Telisotuzumab vedotin monotherapy in patients with previously treated c-Met–overexpressing non-squamous EGFR wildtype advanced NSCLC: Primary analysis of the LUMINOSITY trial.
Telisotuzumab vedotin单药治疗既往接受过治疗的c-Met过表达非鳞状EGFR野生型晚期NSCLC患者：LUMINOSITY试验的主要分析
讲者：David Ross Camidge, MD, PhD | University of Colorado Cancer Center
口头摘要速递专场（Rapid Oral Abstract Session）
转移性非小细胞肺癌
摘要号：8513
A multinational pivotal study of sunvozertinib in platinum pretreated non-small cell lung cancer with EGFR exon 20 insertion mutations: Primary analysis of WU-KONG1 study.
一项舒沃替尼治疗铂类药物经治的EGFR 20号外显子插入突变非小细胞肺癌的多国关键性研究：WU-KONG1研究的主要分析
讲者：杨志新 （中国）台湾大学医学院附设医院癌医中心分院
摘要号：8514
Phase Ia/Ib trial of zongertinib (BI 1810631), a HER2-specific tyrosine kinase inhibitor (TKI), in patients (pts) with HER2 aberration-positive solid tumors: Updated Phase Ia data from Beamion LUNG-1, including progression-free survival (PFS) data.
zongertinib（BI 1810631）（一种HER2特异性TKI）在HER2异常阳性实体瘤患者中的Ia/Ib期试验：更新了来自Beamion LUNG-1的Ia期数据，包括无进展生存期（PFS）数据
讲者：John Heymach, MD, PhD | Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
摘要号：8515
Efficacy and safety of erdafitinib in adults with NSCLC and prespecified fibroblast growth factor receptor alterations in the phase 2 open-label, single-arm RAGNAR trial.
在II期开放标签、单臂RAGNAR试验中，Erdafitinib在NSCLC和预设FGFR变异成人患者中的疗效和安全性
讲者：Martin H. Schuler, MD | Department of Medical Oncology, West German Cancer Center, University Hospital Essen
摘要号：8516
Amivantamab plus lazertinib in atypical EGFR-mutated advanced non-small cell lung cancer (NSCLC): Results from CHRYSALIS-2.
Amivantamab联合lazertinib治疗非经典EGFR突变的晚期非小细胞肺癌（NSCLC）：来自CHRYSALIS-2的结果
讲者：Byoung Chul Cho, MD, PhD | Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine
摘要号：8517
A phase 2 study of amivantamab plus lazertinib in patients with EGFR-mutant lung cancer and active central nervous system disease.
amivantamab联合lazertinib治疗EGFR突变肺癌和活动性中枢神经系统疾病患者的2期研究
讲者：Helena Alexandra Yu, MD | Department of Medicine, Medical Oncology, Memorial Sloan Kettering Cancer Center
摘要号：8518
Safety and efficacy of osimertinib plus consolidative stereotactic ablative radiation (SABR) in advanced EGFR mutant non-small cell lung cancer (NSCLC): Results from a multi-center phase II trial.
奥希替尼联合巩固立体定向消融放疗（SABR）治疗晚期EGFR突变非小细胞肺癌（NSCLC）的安全性和疗效：一项多中心II期试验的结果
讲者：Sawsan Rashdan, MD | UT Southwestern
摘要号：8519
Lorlatinib in TKI naïve, advanced ROS1-positive non-small-cell lung cancer: A multicenter, open-label, single-arm, phase 2 trial.
洛拉替尼治疗TKI初治的晚期ROS1阳性非小细胞肺癌：一项多中心、开放标签、单臂、II期试验
讲者：Beung Chul AHN, MD | Center for Lung Cancer, Division of Hematology and Oncology, Department of Internal Medicine, Research Institute and Hospital, National Cancer Center
摘要号：8520
Efficacy and safety of taletrectinib in patients with advanced or metastatic ROS1+ non–small cell lung cancer: The phase 2 TRUST-I study.
Taletrectinib在晚期或转移性ROS1+非小细胞肺癌患者中的疗效和安全性：2期TRUST-I研究
讲者：李玮 上海市肺科医院
摘要号：8521
Efficacy and safety of sigvotatug vedotin, an investigational ADC, in NSCLC: Updated phase 1 results (SGNB6A-001).
Sigvotatug vedotin（一种正在研究的ADC）在NSCLC中的疗效和安全性：更新的I期结果（SGNB 6A-001）
讲者：Solange Peters, MD, PhD | Centre Hospitalier Universitaire Vaudoi
局晚期非小细胞肺癌/小细胞肺癌/其他胸部肿瘤
摘要号：LBA8010
Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with resectable NSCLC: 4-year update from CheckMate 816.
新辅助纳武利尤单抗+化疗对比化疗在可切除NSCLC患者中的应用：CheckMate 816的4年更新
讲者：Jonathan Spicer, MD, PhD, FRCPC | McGill University Health Centre
摘要号：8011
Outcomes with perioperative durvalumab (D) in pts with resectable NSCLC and baseline N2 lymph node involvement (N2 R-NSCLC): An exploratory subgroup analysis of AEGEAN.
围手术期度伐利尤单抗治疗可切除NSCLC和基线N2淋巴结受累（N2 R-NSCLC）患者的结局：AEGEAN的探索性亚组分析
讲者：John Heymach, MD, PhD | The University of Texas MD Anderson Cancer Center
摘要号：8012
Health-related quality of life (HRQoL) outcomes from the randomized, double-blind phase 3 KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC).
围手术期帕博利珠单抗治疗早期非小细胞肺癌（NSCLC）的随机、双盲、3期KEYNOTE-671研究的健康相关生活质量（HRQoL）结局
讲者：Marina Chiara Garassino, MD | Fondazione IRCCS Istituto Nazionale dei Tumori (currently at Knapp Center for Biomedical Discovery, University of Chicago Medicine & Biological Sciences, Chicago, IL, USA)
摘要号：8013
Global retrospective study comparing consolidation ALK tyrosine kinase inhibitors (TKI) to durvalumab (durva) or observation (obs) after chemoradiation (CRT) in unresectable locally-advanced ALK+ non-small cell lung cancer (NSCLC).
一项全球回顾性研究，在不可切除的局晚期ALK阳性NSCLC患者中，比较接受放化疗（CRT）后使用ALK-TKI进行巩固治疗与使用度伐利尤单抗或观察的效果
讲者：Ritujith Jayakrishnan | Yale New Haven Hospital
摘要号：8014
Overall survival of adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line treatment for extensive-stage small cell lung cancer.
阿得贝利单抗+化疗序贯胸部放疗一线治疗广泛期小细胞肺癌的OS
讲者：陈大卫 山东第一医科大学附属肿瘤医院
摘要号：8015
DeLLphi-301: Tarlatamab phase 2 trial in small cell lung cancer (SCLC)—Efficacy and safety analyzed by presence of brain metastasis.
DeLLphi-301：Tarlatamab在小细胞肺癌（SCLC）中的II期试验-通过脑转移情况分析疗效和安全性
讲者：Anne-Marie C. Dingemans, MD, PhD | Erasmus MC Cancer Institute
摘要号：8016
Smoking history requirement and lung cancer (LC) screening (LCS) eligibility disparities.
吸烟史要求和肺癌（LC）筛查（LCS）资格差异
讲者：Matthew Smeltzer, PhD, MS | University of Memphis, School of Public Health
摘要号：8017
Niraparib and dostarlimab efficacy in patients with platinum-sensitive relapsed mesothelioma: MIST5, a phase IIa clinical trial.
尼拉帕利和dostarlimab在铂敏感性复发性间皮瘤患者中的疗效：MIST5，一项IIa期临床试验
讲者：Dean Anthony Fennell, MD, FRCP | University of Leicester & University Hospitals of Leicester NHS Trust
摘要号：8018
ctDNA-Lung-DETECT: ctDNA outcomes for resected early stage non-small cell lung cancers at 12 months.
ctDNA-Lung-DETECT：可切除的早期非小细胞肺癌12个月时的ctDNA结局
讲者：Sam Khan, PhD, MBBS | Department of Medical Oncology and Hematology, University Health Network, Princess Margaret Cancer Centre
扫码关注专栏，与肿瘤资讯不见不散！
排版编辑：肿瘤资讯-TY
苏公网安备 32059002004080号
